Liu Tongri
Chairman and CEO of Beijing Yisheng Biotechnology Co
Liu Tongri was recognized as a leading talent in the "New National Gate" Project of Daxing District in 2022. He holds dual bachelor's degrees in Biological Science and Economics from Peking University, as well as a doctoral degree in Biochemistry from the University of Oxford.
After graduation, he has been engaged in the research and development of cell therapy drugs based on iPSC in the United Kingdom, and is directly involved in the entire process of iPSC research, registration, and clinical transformation.
In 2021, after accumulating a wealth of experience in the industrialization of pluripotent stem cells and conducting thorough market research, Liu, together with two co-founders, established Yisheng Biotechnology.
The company has a wholly-owned research and development laboratory, Aceso BioSciences, in Cambridge, the UK, and has rapidly advanced product technology development in both China and the UK.